Particle Sciences & Pernix Therapeutics Enter Development Agreement
Particle Sciences, Inc. recently announced it is developing with Pernix Therapeutics a new topical dermatology product for the pediatric market.
“There are multiple treatments for many pediatric skin conditions,” said Mark Mitchnick, CEO of Particle Sciences. “The unmet need is in the delivery of these agents via a more convenient, and improved vehicle. Particle Sciences is applying advanced drug delivery and formulation technologies to an established pediatric product category. For parents, this product is designed to be a potentially better and easier-to-use product.”
“We are enthusiastic about working with Particle Sciences for this product candidate, which may be another opportunity to further expand our pediatric product line,” added Cooper Collins, Pernix Therapeutics’ President and CEO.
Particle Sciences is an integrated provider of drug development services focusing on emulsions, gels, micro and nano-particulates, drug/device combination products and highly potent compounds across all dosage forms. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. Visit http://www.particlesciences.com/, email info@particlesciences.com, or contact us at (610) 861–4701 for more information.
Total Page Views: 975
